Molecular staging and the selection of therapy for non-small cell lung cancer.
Publication
, Journal Article
D'Amico, TA
Published in: Semin Thorac Cardiovasc Surg
2005
The stage-specific selection of therapy is the standard for patients with non-small cell lung cancer. Investigation of the molecular biology of lung cancer has provided pathways and targets that may be used to improve the efficacy of therapy and improve the survival for patients with lung cancer.
Duke Scholars
Published In
Semin Thorac Cardiovasc Surg
DOI
ISSN
1043-0679
Publication Date
2005
Volume
17
Issue
3
Start / End Page
180 / 185
Location
United States
Related Subject Headings
- Respiratory System
- Prognosis
- Neoplasm Staging
- Lung Neoplasms
- Humans
- Cyclooxygenase 2 Inhibitors
- Carcinoma, Non-Small-Cell Lung
- Biomarkers, Tumor
- Antibodies, Monoclonal
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
D’Amico, T. A. (2005). Molecular staging and the selection of therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg, 17(3), 180–185. https://doi.org/10.1053/j.semtcvs.2005.06.011
D’Amico, Thomas A. “Molecular staging and the selection of therapy for non-small cell lung cancer.” Semin Thorac Cardiovasc Surg 17, no. 3 (2005): 180–85. https://doi.org/10.1053/j.semtcvs.2005.06.011.
D’Amico TA. Molecular staging and the selection of therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2005;17(3):180–5.
D’Amico, Thomas A. “Molecular staging and the selection of therapy for non-small cell lung cancer.” Semin Thorac Cardiovasc Surg, vol. 17, no. 3, 2005, pp. 180–85. Pubmed, doi:10.1053/j.semtcvs.2005.06.011.
D’Amico TA. Molecular staging and the selection of therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2005;17(3):180–185.
Published In
Semin Thorac Cardiovasc Surg
DOI
ISSN
1043-0679
Publication Date
2005
Volume
17
Issue
3
Start / End Page
180 / 185
Location
United States
Related Subject Headings
- Respiratory System
- Prognosis
- Neoplasm Staging
- Lung Neoplasms
- Humans
- Cyclooxygenase 2 Inhibitors
- Carcinoma, Non-Small-Cell Lung
- Biomarkers, Tumor
- Antibodies, Monoclonal
- 3202 Clinical sciences